McConnell Michelle S, Byers Robert H, Frederick Toni, Peters Vicki B, Dominguez Kenneth L, Sukalac Thom, Greenberg Alan E, Hsu Ho-Wen, Rakusan Tamara A, Ortiz Idith R, Melville Sharon K, Fowler Mary Glenn
Division of Applied Public Health Training, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):488-94. doi: 10.1097/01.qai.0000134744.72079.cc.
In the United States, HIV-infected children and adolescents are aging and using antiretroviral (ARV) therapy for extended periods of time.
To assess trends in ARV use and long-term survival in an observational cohort of HIV-infected children and adolescents in the United States.
The Pediatric Spectrum of HIV Disease Study (PSD) is a prospective chart review of more than 2000 HIV-infected children and adolescents. Patients were included in the analysis from enrollment until last follow-up.
Triple-ARV therapy use (for 6 months or more) increased from 27% to 66% during 1997 to 2001 (P < 0.0001, chi for trend). The proportion of patients receiving 3 or more sequential triple-therapy regimens also increased from 4% to 17% during 1997 to 2001 (P < 0.0001, chi for trend), however, and the durability of triple-therapy regimens decreased from 13 to 7 months from the first to third regimen. Survival rates for the 1997 to 2001 birth cohorts were significantly better than for the 1989 to 1993 and 1994 to 1996 cohorts (P < 0.0001).
Survival rates in the PSD cohort have increased in association with triple-ARV therapy use. With continued changes in ARV regimens, effective modifications in ARV therapy and the sustainability of gains in survival need to be determined.
在美国,感染艾滋病毒的儿童和青少年正逐渐长大,并长期使用抗逆转录病毒(ARV)疗法。
评估美国感染艾滋病毒的儿童和青少年观察队列中抗逆转录病毒疗法的使用趋势和长期生存率。
儿童艾滋病毒疾病谱研究(PSD)是一项对2000多名感染艾滋病毒的儿童和青少年进行的前瞻性病历回顾。患者从入组至最后一次随访均纳入分析。
1997年至2001年期间,三联抗逆转录病毒疗法(使用6个月或更长时间)的使用率从27%增至66%(趋势检验P<0.0001,卡方检验)。1997年至2001年期间,接受3种或更多连续三联疗法方案的患者比例也从4%增至17%(趋势检验P<0.0001,卡方检验),然而,三联疗法方案的持续时间从第一个方案到第三个方案从13个月降至7个月。1997年至2001年出生队列的生存率显著高于1989年至1993年和1994年至1996年队列(P<0.0001)。
PSD队列中的生存率随着三联抗逆转录病毒疗法使用率的增加而提高。随着抗逆转录病毒疗法方案的持续变化,需要确定抗逆转录病毒疗法的有效调整以及生存率提高的可持续性。